BACKGROUND: Tumor stage at diagnosis often varies by racial/ethnic group, possibly because of inequitable health care access. Within the Department of Defense (DoD) Military Health System, beneficiaries have equal health care access. The objective of this study was to determine whether tumor stage differed between whites and blacks with breast, cervical, colorectal, and prostate cancers, which have effective screening regimens, based on data from the DoD Automated Cancer Tumor Registry from 1990 to 2003. METHODS: Distributions of tumor stage (localized vs nonlocalized) between whites and blacks in the military were compared stratified by sex, active duty status, and age at diagnosis. Logistic regression was used to further adjust for age, marital status, year of diagnosis, geographic region, military service branch, and tumor grade. Distributions of tumor stage were then compared between the military and general populations. RESULTS: Racial differences in the distribution of stage were significant only among nonactive duty beneficiaries. After adjusting for covariates, earlier stages of breast cancer after age 49 years and prostate cancer after age 64 years were significantly more common among white than black nonactive duty beneficiaries (P < .05), although the absolute difference was minimal for prostate cancer. Racial differences in stage for cervical and colorectal cancers were not significant after adjustment. Compared with the general population, racial differences in the military were similar or were slightly attenuated. CONCLUSIONS: Racial disparities in stage at diagnosis were apparent in the DoD equal-access health care system among older nonactive duty beneficiaries. Socioeconomic status, supplemental insurance, cultural beliefs, and biologic factors may be related to these results. Cancer 2012;118:1397-
of Defense (DoD) Military Health System provides a unique opportunity to study potential racial disparities, because it provides equal access to health care without regard to race or socioeconomic status. A recent survey of DoD beneficiaries indicated that self-reported cancer screening rates were higher and racial/ethnic disparities in cancer screening rates were lower compared with those in the general US population. 11 It is unclear whether these findings translate to decreased racial disparities in tumor stage at diagnosis. Previous studies among combined DoD active duty and nonactive duty beneficiaries produced evidence of racial variation by tumor stage at diagnosis for colorectal and breast cancers. [12] [13] [14] However, it was not known whether racial differences varied by active duty status or persisted after adjusting for other covariates.
The objective of the current study was to conduct a DoD-wide comparison of tumor stage at diagnosis between whites and blacks for 4 cancers (breast, cervical, colorectal, and prostate). These cancer sites were selected because racial variations in stage at diagnosis observed in the general population may be attributable in part to access to the established screening tests. Comparisons were made between white and black beneficiaries by sex, active duty status, and age at diagnosis, because active duty personnel may be monitored more closely and because cancer screening practices vary with age. 15 Data on racial differences by tumor stage at diagnosis in the general US population were obtained for comparison. We hypothesized that tumor stage at diagnosis would not differ significantly within the military by race after covariate stratification and adjustment and that any racial differences observed in the military would be less than differences in the general population.
MATERIALS AND METHODS
The Automated Cancer Tumor Registry (ACTUR) was established in 1986 and is the data-collection and clinical tracking system for all cancer cases diagnosed or treated at military treatment facilities among DoD beneficiaries, including active duty military personnel, retired military personnel, and their dependents. Certified cancer registrars at each facility enter and maintain ACTUR data according to state and federal guidelines. The registry includes information on demographic factors (eg, age, race, sex, and geographic location), diagnostic factors (eg, date of diagnosis), and tumor characteristics (eg, histology, stage, and grade). The anatomic sites of the cancers were categorized using the first edition of the International Classification of Diseases for Oncology (ICD-O)  for patients who were diagnosed from 1986 to 1991,   16   the second edition (ICD-O-2) for patients who were diagnosed from 1992 to 2001,  17 and the third edition ICD-O-3 for patients who were diagnosed after 2001 18 ; all diagnoses were recoded by ACTUR personnel using ICD-O-3 codes.
For the purposes of the current study, registry data for patients aged !18 years who were diagnosed from 1990 to 2003 were included. Although all data submitted to ACTUR are reviewed and verified for accurate diagnoses, patients who were diagnosed between 1986 and 1989 were excluded to minimize the possibility of incomplete ascertainment. Procedures were developed with reference to national and state cancer registry guidelines 19, 20 21, 22 When there were multiple records per tumor at the time of diagnosis with different tumor stage codes, the information was chosen as follows: 1) if surgery information was available, then the code associated with the most definitive surgery was selected; and 2) if no surgery information was available, then the most advanced stage code was selected. Cancer-specific age categories were based on American Cancer Society cancer screening recommendations: breast cancer screening with mammography starting at age 40 years, cervical cancer screening with Papanicolaou smears between ages 18 and 69 years, and colorectal and prostate cancer screening starting at age 50 years. 15 Generally, there are few older active duty beneficiaries, especially those who are eligible for Medicare (aged !65 years); however, there are many older nonactive duty beneficiaries, which allowed for further age stratification among this latter group. Therefore, breast, prostate, and colorectal cancers were investigated separately among individuals aged >64 years. Breast cancer also was investigated among women ages 50 to 64 years, because the average age at menopause is 50 years, and it is known that breast cancer etiology varies by menopausal status. Cervical cancer was investigated stratified at age 30 years, because American Cancer Society recommendations change at this age from annually/biannually Original Article to every 2 to 3 years, depending on the method used. Individuals ages 65 to 69 years were not investigated separately for cervical cancer because of their small numbers. For comparison with the general US population, data for patients who were diagnosed from 1990 to 2003 were obtained on breast and cervical cancers among women and on colorectal cancers among both sexes from the 9 original SEER registries (Connecticut, Iowa, New Mexico, Utah, Hawaii, Detroit, San Francisco-Oakland, Atlanta, and Seattle-Puget Sound), which cover about 10% of the US population. 23 Like the ACTUR data, tumor site data were based on ICD-O-3 codes. Stage at diagnosis was determined for each patient according to ''SEER Historical Stage A'' codes (in situ, localized, regional, distant, unstaged; in situ cancers were not included in this analysis). 24 SEER Historical Stage A codes are comparable to the SEER Summary Stage codes (for localized vs regional/distant stages) that were used by ACTUR for breast and cervical cancers. Codes for colorectal cancer stages differ somewhat, in that colorectal tumors with ''invasion of/through serosa'' are classified as localized in SEER and regional in ACTUR. 22 Stage comparisons of prostate cancer between the 2 populations were not conducted, because SEER Historical Stage A codes for prostate cancer group localized and regional disease a single category. 25 The distributions of tumor stage between whites and blacks within the same population were compared when stratified by sex, cancer, categorical age at diagnosis, and active duty status at diagnosis. For active duty members, only univariate analyses were conducted using chi-square tests or Fisher exact tests, because the sample sizes were relatively small. For nonactive duty members and the SEER population, odds ratios (ORs) and 95% confidence intervals (CIs) comparing tumor stage (localized vs regional/distant) between blacks and whites while adjusting for continuous age, marital status (married, single/divorced/separated/widowed, or unknown), year of diagnosis, geographic region (North, South, West, unknown), 26 tumor grade (I, II, III/IV, unknown), and military service branch (Army, Navy, Air Force, Marine, other; ACTUR only) were calculated if cell frequencies for the binary tumor stage variable were at least 10. All analyses were conducted using SAS software version 9.1 (SAS Institute Inc., Cary, NC), and the 2-sided significance level was set at P < .05. The protocol for this study was reviewed and approved by the National Naval Medical Center Institutional Review Board (IRB) and the Armed Forces Institute of Pathology IRB.
RESULTS
For descriptive purposes, the demographic characteristics of included patients in the military by duty status and in the general population are presented by cancer site in Table 1. Among active duty beneficiaries, there were 782 breast cancers, 133 cervical cancers, and 69 colorectal cancers with known tumor stage diagnosed from 1990 to 2003 included among women and 817 prostate cancers and 588 colorectal cancers included among men. No significant differences in tumor stage distribution for any of these cancers were observed between white and black active duty beneficiaries (Table 2) .
Among nonactive duty beneficiaries, there were 16,306 breast cancers, 1196 cervical cancers, and 3679 colorectal cancers included among women and 21,867 prostate cancers and 6016 colorectal cancers included Table 3 ). The percentages of cancers that were localized were significantly greater among whites than blacks for all 4 cancers, even after adjustment. Racial differences did not vary significantly by age. Compared with the general population, racial differences in the percentage of cancers that were localized among nonactive duty beneficiaries tended to be similar or slightly attenuated. For example, in SEER, among women ages 18 to 39 years, 53% of white women and 44% of black women were diagnosed with local breast cancers (difference, 9%) compared with 50% and 51% of their respective counterparts in ACTUR (difference, À1%). Comparisons between the general population and the active duty military population were not conducted, because no significant racial differences were observed among the latter population.
DISCUSSION
The distribution of tumor stage by race did not appear to vary greatly among active duty beneficiaries for the 4 cancers that were studied, but small sample sizes may have resulted in insufficient power to detect true differences. In contrast, racial differences were observed among nonactive duty beneficiaries, particularly among older Original Article
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Cancer individuals with breast or prostate cancers. Nonetheless, the racial differences observed in the military appeared to be similar or attenuated compared with the general population; the racial difference in the percentage of cancers that were localized was smaller for breast cancer among young women who were nonactive duty beneficiaries compared with young women in the general population. Our results among nonactive duty beneficiaries were in agreement with a previous DoD-wide breast cancer study, although the calendar years differed.
14 Our findings further indicated that significant racial differences exist after covariate adjustment and occur within age groups for which mammography is recommended. It is unclear why racial differences in breast cancer stage increased with age in the military but not in the general population. After covariate adjustment, our findings indicated that stage at diagnosis for colorectal cancer did not differ significantly between whites and blacks, which is contradictory to previous unadjusted studies among DoD beneficiaries. 12, 13 This inconsistency may have resulted from differences in study populations, because 1 of the previous studies 12 was based on registry data from 1 DoD medical center, whereas our study was DoD-wide. Geographic variations in use of health care and physician practice have been observed in the Department of Veterans Affairs health care system, 27 which provides care for Larger racial disparities were observed among older nonactive duty individuals. We can only speculate about the reasons for these disparities. They may be caused by the increased physical or cultural barriers to health care use and variations in health care options among older individuals. These barriers could result in a greater tendency for black individuals to forgo more frequent care and/or postpone seeking medical care until after symptoms appear, thus resulting in a greater proportion of older black beneficiaries diagnosed at later stages of cancer. Although our data did not contain information on the use of cancer screening tests and could not demonstrate any racial differences in cancer screening, it has been observed that perceived cancer risk and cancer screening awareness vary by race. 28, 29 Racial variations in other health insurance (ie, through employment, spouse, or Medicare) also may influence health care seeking behaviors. In addition, it is possible that racial differences in genetics or other biologic factors may result in variations in tumor aggressiveness 30 and, thus, differences in tumor stage at diagnosis.
The main strength of this study was the use of data from a health care system that is based on equal access to assess racial variations. Limitations of the study included the small numbers of specific cancers by race among active duty beneficiaries. Such numbers may have limited the power to detect racial differences. Second, the grouped categorization of localized and regional prostate cancers in the SEER data precluded us from comparing the magnitude of the racial difference in tumor stage between the 2 populations for this cancer site. There also is the possibility of under reporting in ACTUR. Although DoD policies require cancer cases to be reported to ACTUR, some military treatment facilities, especially small ones, may not have reported their cancer patients. Although the extent of the under reporting is not known, differential reporting of tumor stage by race would have to exist to explain the observed differences. In addition, there is the possibility of selection bias of the patients who were included in the study, because beneficiaries have to be seen at a DoD medical center to be reported to ACTUR, and beneficiaries who have other health insurance may seek care elsewhere. There would have to be differential selection by stage and race for this to account for the observed differences. If whites have greater access to other health care and are diagnosed elsewhere at earlier stages, then it is possible that our findings may represent an underestimate of the true racial difference in tumor stage at diagnosis among nonactive duty military beneficiaries. Finally, for colorectal cancer, differences in tumor stage criteria between the 2 populations may explain in part the higher percentage of localized tumors in the general population; therefore, the results should be interpreted with caution. However, unless the percentage of tumors with ''invasion of/through serosa'' differed by race, the racial difference in the percentage of localized tumors in the 2 populations should be comparable.
In conclusion, racial disparities in tumor stage at diagnosis were not observed in the DoD Military Health System among active duty beneficiaries, but disparities were apparent among older nonactive duty beneficiaries, and whites generally were diagnosed with earlier stage breast and prostate cancers than blacks. Although the DoD system is based on equal access, racial variation in socioeconomic status and supplemental insurance still may affect tumor stage at diagnosis. Therefore, more studies are needed to assess the independent impact of these and other possible factors.
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